PharmaCyte Biotech’s “Release Testing” Last Critical Event Before Submission of Investigational New Drug Application
12 nov. 2019 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Nov. 12, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reduced a long list of FDA-required items to just one last important component—release testing—before it can...
PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trial
28 oct. 2019 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Oct. 28, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has a technology that could very well change the way a host of hard-to-treat diseases are treated for the foreseeable...
PharmaCyte Biotech Closer to Submitting IND with Successful Completion of Clinical Trial Product
16 oct. 2019 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Oct. 16, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has now moved one step closer to submitting an Investigational New Drug application (IND) to the U.S. Food and Drug...
PharmaCyte Biotech's Pancreatic Cancer Therapy Production in Final Days of Key Manufacturing Run
23 sept. 2019 09h00 HE
|
PharmaCyte Biotech
NEW YORK, NY, Sept. 23, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) and its partner, Austrianova, along with the company’s cellular biologist, David Judd, are all more confident than...
PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA
04 févr. 2019 09h20 HE
|
PharmaCyte Biotech
NEW YORK, NY, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Clinical stage biotechnology company PharmaCyte Biotech (OTCQB: PMCB) is now closer than ever to reaching what would be a monumental milestone in the...
World-Renowned Oncologist Bullish on Potential of PharmaCyte’s Technology, Clinical Trial in Pancreatic Cancer
23 janv. 2019 09h25 HE
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 23, 2019 (GLOBE NEWSWIRE) -- With PharmaCyte Biotech, Inc.’s (OTCQB: PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct...
PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology
06 juin 2018 09h20 HE
|
PharmaCyte Biotech
NEW YORK, N.Y., June 06, 2018 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB: PMCB) is closing in on what will be a landmark event in this small company’s history—a clinical trial in the United...
PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer
21 mai 2018 09h20 HE
|
PharmaCyte Biotech
NEW YORK, NY, May 21, 2018 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reached the proverbial “home stretch” regarding its efforts to submit an Investigational New Drug Application...